Group 1: Earnings Performance - biote Corp. reported quarterly earnings of $0.1 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, but down from $0.14 per share a year ago, representing an earnings surprise of +66.67% [1] - Over the last four quarters, biote Corp. has surpassed consensus EPS estimates four times [2] - The company posted revenues of $48.86 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.37%, and down from $49.17 million year-over-year [2] Group 2: Stock Performance and Outlook - biote Corp. shares have declined approximately 32.5% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at $0.10 for the coming quarter and $0.61 for the current fiscal year [4][7] - The estimate revisions trend for biote Corp. was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Products industry, to which biote Corp. belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact biote Corp.'s performance [5]

Core Viewpoint - Groupon reported quarterly earnings of $0.46 per share, significantly exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, marking an earnings surprise of +2,400% [1] - The company has shown consistent performance, surpassing consensus EPS estimates three times over the last four quarters [2] Financial Performance - Groupon's revenues for the quarter ended June 2025 were $125.7 million, surpassing the Zacks Consensus Estimate by 2.32% and showing a slight increase from $124.61 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $121.43 million, while for the current fiscal year, it is $0.30 on revenues of $500.25 million [7] Stock Performance - Groupon shares have increased approximately 150.5% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Internet - Commerce industry, to which Groupon belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

分组1 - Senseonics Holdings reported a quarterly loss of $0.02 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company posted revenues of $6.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.46%, and up from $4.86 million year-over-year [2] - Senseonics has surpassed consensus revenue estimates three times over the last four quarters [2] 分组2 - The stock has underperformed, losing about 3.4% since the beginning of the year, while the S&P 500 gained 7.1% [3] - The company's earnings outlook and estimate revisions will be crucial for future stock performance [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $10.03 million, and -$0.07 on revenues of $36.46 million for the current fiscal year [7] 分组3 - The Medical Info Systems industry, to which Senseonics belongs, is currently in the top 30% of Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5]

Core Viewpoint - Adma Biologics reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.13 per share a year ago, indicating a positive earnings surprise of +7.14% [1] Financial Performance - The company achieved revenues of $121.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.73% and up from $107.19 million in the same quarter last year [2] - Over the last four quarters, Adma Biologics has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Adma Biologics shares have increased approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.17 on revenues of $130.7 million, and for the current fiscal year, it is $0.61 on revenues of $505.8 million [7] - The company's earnings outlook will be crucial for assessing future stock performance, especially in light of recent earnings report and management commentary [4][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8]

Company Performance - Aligos Therapeutics reported a quarterly loss of $1.53 per share, which was better than the Zacks Consensus Estimate of a loss of $2.35, representing an earnings surprise of +34.89% [1] - The company posted revenues of $0.97 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.5%, and down from $1.06 million a year ago [2] - Over the last four quarters, Aligos has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] Stock Movement and Outlook - Aligos Therapeutics shares have declined approximately 80.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$2.48 on $1 million in revenues, and for the current fiscal year, it is -$9.71 on $2.16 million in revenues [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Aligos belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos's stock performance [5][6]

Financial Performance - Outset Medical reported a quarterly loss of $0.84 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.76, and an improvement from a loss of $7.05 per share a year ago, representing an earnings surprise of +52.27% [1] - The company posted revenues of $31.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.54% and up from $27.39 million in the same quarter last year [2] Stock Performance - Outset Medical shares have declined approximately 15.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Outset Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$1.61 on revenues of $30.4 million, and for the current fiscal year, it is -$5.99 on revenues of $121.7 million [7] - The estimate revisions trend for Outset Medical was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Inotiv, Inc. reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of +20.00% [1] - The company posted revenues of $130.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.94% and showing an increase from year-ago revenues of $105.79 million [2] - Over the last four quarters, Inotiv has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Inotiv shares have declined approximately 49.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.08 on revenues of $130.9 million, and for the current fiscal year, it is -$0.86 on revenues of $499.62 million [7] Industry Outlook - The Medical - Drugs industry, to which Inotiv belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Inotiv's stock performance [5]

Core Insights - CareDx reported quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share, and down from $0.25 per share a year ago, representing an earnings surprise of -16.67% [1] - The company posted revenues of $86.68 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.45%, and down from $92.27 million year-over-year [2] - CareDx shares have declined approximately 40% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $94.77 million, and for the current fiscal year, it is $0.60 on revenues of $371.5 million [7] - The estimate revisions trend for CareDx was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which CareDx belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Establishment Labs Holdings Inc., another company in the same industry, is expected to report a quarterly loss of $0.54 per share, with revenues anticipated to be $51.61 million, reflecting a 17% increase year-over-year [9][10]

Company Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.35 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, and an improvement from a loss of $0.50 per share a year ago, resulting in an earnings surprise of +14.63% [1] - The company posted revenues of $79.18 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but showing significant growth from year-ago revenues of $53.35 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 40.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $83.74 million, and for the current fiscal year, it is -$1.49 on revenues of $325.61 million [7] Industry Outlook - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of stocks in this industry can be significantly influenced by the overall industry outlook, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Steris reported quarterly earnings of $2.34 per share, exceeding the Zacks Consensus Estimate of $2.32 per share, and up from $2.03 per share a year ago, representing an earnings surprise of +0.86% [1] - The company posted revenues of $1.39 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.36%, compared to $1.28 billion in the same quarter last year [2] - Over the last four quarters, Steris has surpassed consensus EPS estimates three times and topped consensus revenue estimates once [2] Future Outlook - The immediate price movement of Steris shares will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.39 on revenues of $1.41 billion, and for the current fiscal year, it is $10.12 on revenues of $5.83 billion [7] Industry Context - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Steris's stock performance [5][6]